Equity Closing Update 28th November 2013 Sensex 20534.91 114.65 Nifty 6091.85 34.75 Nifty Future 6160.00 43.75 Market Wrap-Up: Who Moved and Why
High volatility was witnessed as key benchmark indices
• Gujarat NRE Coke spurts after multiple block deals.
regained strength soon after trimm ing intraday gains in mid-
• Bank of Baroda turns volatile as board to consider
afternoon trade. The market was volatile as traders rolled
over positions in the futures & opt ions (F&O) segment from
the near month November 2013 series to December 2013
Dr Reddy's Labs gains on likely boost in Toprol sales.
• Nestle India drops as overseas parent says no plan to hike
the market, was positive. Gains in Asian and European
Godrej Consumer Products surges after block deals.
Asian and European stocks rose after US employment and
• M&M gains ahead of press conference.
consumer confidence reports boosted optimism in the world's
Fina ncial gains over 4% in two sessions.
Benchmark Nifty Intraday C BSE Metal Oil & Gas Gainers/ Global Market at 3.30 PM Losers BSE 200 Coromandel Int Adani Enterpris Shanghai rakash Asso Hang- Seng GMR Infra Pipavav Defence Prestige US Markets Market Breadth DJIA (Fut.) Exchange Unchanged Nasdaq (Fut.) S&P 500 (Fut.) RR, All Rights Reserved Catch us on live chat Click the below mentioned link and like RR Facebook pag e. (9:00 a.m to 6:00 p.m.) For Further Details/Clarifications please contact:
RR Information & Investment Research Pvt. Ltd. 47, MM Road Jhandewalan New Delhi-110055 (INDIA) Tel: 011-23636362/63
RR Research Products and Services:
Online Equity Calls during Market Hours (9:00 AM to 3:30 PM) Online Commodity Calls during Market Hours (10:00 AM to 11:30 PM) Online Currency Calls during Market Hours (10:00 AM to 5:00 PM)
Equity Weekly Report Debt Weekly Report Commodity Weekly Report Currency Weekly Report
Fundamental Research
Global Market Analysis Economic Analysis Industry Analysis Company Research & Valuations Result Updates News Updates Events Updates
IPO / FPO Analysis Mutual Fund Analysis Insurance Analysis
Investment Monitor – The complete monthly magazine design for Indian investors
Join us on face book: RR, All rights reserved Disclaimer: Kindly read the Risk Disclosure Documents carefully before investing in Equity Shares, Derivatives or other instruments traded on the Stock Exchanges. RR would include RR Financial Consultants Ltd. and its subsidiaries, group companies, employees and affiliates. The information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of RR. The information contained herein is obtained from public sources and sources believed to be reliable, but independent verification has not been made nor is its accuracy or completeness guaranteed. RR or their employees may have or may not have an outstanding buy or sell position or holding or interest in the products mentioned herein. The contents and the information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial and insurance products and instruments. Nothing in this report constitutes investment, legal, accounting and/or tax advice or a representation that any investment or strategy is suitable or appropriate to recipients specific circumstances. The securities and products discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs. Please note that fixed deposits, bonds, debentures are loans/lending instruments and the investor must satisfy himself/herself on the financial health of the company/bank/institution before making any investment. RR and/or its affiliates take no guarantee of soundness of any company or scheme. RR has/will make available all required information to the prospective investor if asked for in respect of any scheme/fixed deposit/bond/loan/debenture. RR is only acting as a broker/distributor and is not representing any company in any manner except to distribute its schemes. Mutual Fund Investments are subject to market risks, read the offer document carefully before investing. Any recipient herein may not take the content in substitution for the exercise of independent judgment. The recipient should independently evaluate the investment risks of any scheme of a mutual fund. RR and its affiliates accept no liability for any loss or damage of any kind arising out of the use of any information contained herein. Past performance is not necessarily a guide to future performance. Actual results may differ materially from those set forth in projections. RR may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. The information herein is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject RR and its affiliates to any registration or licensing requirement within such jurisdiction. The securities and products described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction(s). The display, description or references to any products, services, publications or links herein shall not constitute an endorsement by RR. Insurance is a subject matter of solicitation. Kindly also note all the risk disclosure documents carefully before investing in Equity Shares, IPO’s, Mutual Fund Schemes, Insurance Schemes, Fixed Deposit schemes, Debt offers, Hybrid Instruments, or other instruments traded on Stock Exchanges or otherwise. Prospective investors can get all details and information from the sites of SEBI, IRDA, AMFI or respective Mutual Fund Companies, Insurance Companies, Rating Agencies, Stock Exchanges and individual corporate websites. Prospective investors are advised to fully satisfy themselves before making any investment decision NSE - INB 231219636, INF 231219636 BSE - INB 011219632, NCDEX Membership No: 00635 | MCX Membership No: 28850 | SEBI Registration No: MCX-SX: INE261219636 SEBI Registration No: NSE Currency: INE231219636 About RR RR is first generation business set up in 1986. Shri. Rajat Prasad, a professional qualified Chartered Accountant, is the main founder. He is the architect of its growth and in the last decade has steered the group to be a diverse and respected financial and Insurance Services Organization with nationwide presence with offices in more than 100 cities and a team of 800 Employees. RR has the presence in all metro cities and towns across the length and breadth of the country. RR is headquartered in New Delhi, Capital of India with regional offices in Mumbai, Ahmedabad, Baroda, Jaipur, Chandigarh, Lucknow, Calcutta, Bangalore, Chennai, Noida and Dehradun. It has Associate offices in other cities and Locations totalling 600 locations & 100 cities. It has agent presence in over 500 cities across the country. RR is the only Company in India which provides research based seamless service to its customers through own offices, franchisees and agents. About RR Research RR Research provides unbiased and independent research in Equity, Commodity, Currency, Fixed Income, Debt Market, Mutual Funds, and Insurance. The research team consists of more than 10 analysts, most of which are CAs and MBAs from premier business school with experience ranging from 0 to 10 years. The team is equipped with state of the art analysis tools, software. The research team is engaged in almost every activities of the capital market. In the fundament research front, the team is involved in Economic Analysis, Sectoral Analysis, Company Coverage and Updates. In the trading front, dedicated technical team is employed to provide online technical calls, trading tips, derivative strategies to clients. The team is online during the market hours and anyone through our website can chat live with analysts and can solve any investment related query. The team has extensive network of industry contacts and regularly attending analyst meets/ conference calls to get insight of the company. On regular basis, the team shares its view with leading electronic & print media houses. RR, All rights reserved
8. Kongress für Infektionskrankheiten und Tropenmedizin Aktuelles zur Tuberkulose Prof. Dr. med. Emil C. Reisinger Abteilung für Tropenmedizin und Infektionskrankheiten der Klinik und Poliklinik für Innere Medizin Universität Rostock Ernst-Heydemannstr. 6 D-18057 Rostock Tel.: 0049-381-494-7510 od. 7511 Fax: 0049-381-494-7509 E-mail: emil.reisinger@medizin.uni-rostock.de
DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Fadwa Almanakly, Pharm.D. Associate Director, Advertising and Promotions Bayer HealthCare Pharmaceuticals Inc. 6 West Belt Wayne, NJ 07470-6806 RE: NDA 21-225 Mirena® (levonorgestrel-releasing intrauterine system) MACMIS # 18166 The Division of Drug Marketing, A